Tradestie Institutional Equity Comparison Engine

MRNA vs ONC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ONC Overall Edge

ONC Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BeOne Medicines Ltd. American Depositary Shares (ONC) driven by superior Growth & Margin, Options & Structure while MRNA counters with relative strength in Valuation, Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus ONC at 36.2x Forward P/E and 17.8% operating margin (+33.8% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against ONC sits in UNCLASSIFIED (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
MRNA 23.0x vs ONC 36.2x Fwd P/E
Growth & Margin Winner ONC
Op Margin -80.8% vs 17.8% ยท YoY +29.2% vs +33.8%
Momentum & Technical Winner MRNA
1Y +706.5% vs +10.5% ยท 52W Pos 67% vs 80%
Options & Structure Winner ONC
CONSOLIDATION (52nd %ile IV) vs UNCLASSIFIED (23rd %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
ONC NASDAQ
BeOne Medicines Ltd. American Depositary Shares
Pharmaceutical Preparations
$390.94
-2.19% 1D
Market Cap $45.7B
1M Return +2.27%
1Y Return +10.5%
Forward P/E 36.2x
Unified AI Score
48.0 / 100 HOLD
Tech 34.0 Fund 43.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +706.45% ONC +10.5% Spread: +695.95 pp (MRNA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MRNA TTM Op. Margin: -80.8% ONC TTM Op. Margin: 17.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs ONC. Trailing 12-month operating profitability (MRNA -80.8% vs ONC 17.8%) and valuation multiples (MRNA 23.0x vs ONC 36.2x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (3) vs ONC (7)
Institutional Metric MRNA ONC Criterion Row Winner
Market Capitalization Scale $80.7B $45.7B Larger Scale MRNA
Trailing P/E Ratio Valuation 23.0x 51.2x Lower Multiple MRNA
Forward P/E Ratio Valuation 23.0x 36.2x Lower Multiple MRNA
Revenue Growth (YoY) Growth +29.2% +33.8% Higher Growth ONC
Operating Margin (TTM) Profitability -80.8% 17.8% Higher Margin ONC
Net Profit Margin Profitability -110.5% 13.9% Higher Margin ONC
Return on Equity (ROE) Capital Efficiency -34.5% 18.4% Higher ROE ONC
52-Week Range Position Momentum 67% ($22โ€“$281) 80% ($254โ€“$425) Stronger Trend ONC
Beta / 30D Volatility Risk Regime 2.23ฮฒ ยท 78% Vol 0.67ฮฒ ยท 37% Vol Lower Realized Risk ONC
Unified Institutional Score Composite Signal 40.3 / 100 (SELL) 48.0 / 100 (HOLD) Higher Composite ONC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs ONC Buy Guide
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ONC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live ONC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor ONC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.